Fintech
Axyon AI Closes a 3.9 Million Investment Round
In 2016, Axyon AI was created to develop innovative AI-based predictive solutions dedicated to helping corporate asset managers generate winning investment strategies. By integrating advanced predictions based on AI models and active indices, Axyon enables asset managers to operate in complex market dynamics with greater precision.
Axyon AI, a fintech company that deals with predictive artificial intelligence and deep learning solutions for corporate asset managers has closed a 3.9 million euro investment round.
Of these, 2.3 million euros are in liquidity, while the remaining 1.6 million euros will be guaranteed by the conversion of the convertible notes issued in 2022 and subscribed, among others, by the Startup Rilancio Fund of CDP Venture Capital, ING Ventures and UniCredit.
The fundraising led by the US venture capital company Montage Ventures also saw the participation of The Techshop SGR, as well as other angel investors. The investment will serve to consolidate the startup’s commercial expansion and technological development initiatives.
Read more about Axyon AI and its latest financing round, and find the most important business news of the day with our companion app Born2Invest.
Axyon and AI
In 2016, Axyon AI was created to develop innovative AI-based predictive solutions dedicated to helping corporate asset managers generate winning investment strategies. By integrating advanced predictions based on AI models and active indices, Axyon enables asset managers to operate in complex market dynamics with greater precision.
“This fundraising, thanks to the partnership with Montage Ventures and The Techshop, represents a significant step forward for us – comments Daniele Grassi, CEO and co-founder of Axyon AI – For us an era of innovation and commercial expansion opens up, towards the realization of our mission and increasingly accurate and reliable AI solutions for investment management.”
__
(Featured image by geralt via Pixabay)
DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.
First published in StartupItalia, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.
Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us
-
Business1 week ago
Gold and the Dow Jones Continue Looking Good
-
Impact Investing3 days ago
Shipping Industry: How Small Caps Can Help Reduce Emissions
-
Cannabis1 week ago
Germany’s First Legal Cannabis Club Hands Out Home-Grown Cannabis
-
Biotech5 hours ago
Abbott Presents Innovative Solutions to IDIS to Improve the Treatment of Mitral and Tricuspid Regurgitation